tirzepatide surmount 2 for the treatment of obesity: Rationale and design of the clinical development program - Roux - 2023 - Obesity SURMOUNT‐1 study design. This is

2019 Aug 19;18:631-643

Phase II - larger number of patients, designed to evaluate the safety and efficacy of the medicine and to determine if different dosages of the treatment have different effects

Liquid liposomal supplements generally offer the best absorption rates because the phospholipids are already in a stable, liquid state

Less common but more serious side effects include kidney failure, pancreatitis, gallbladder issues, and thyroid tumors

Rotating injection sites with each doserather than using the same location repeatedlyallows tissue recovery and reduces cumulative irritation

UV radiation and, to a lesser extent, visible light accelerate the oxidation of benzyl alcohol to benzaldehyde